Clinical Trial Update: To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of BR-TD-1001 given intramuscularly in healthy children completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Tetanus

Drugs mentioned

• BR-TD-1001

Snippet

Sponsor: Boryung Biopharma Co., Ltd. | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED